Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors
Year: 2024
Type: article
Abstract: The fibroblast growth factor receptor (FGFR) is a crucial receptor tyrosine kinase involved in essential biological processes, including growth, development, and tissue repair. However, FGFR gene mutations, including amplification, fusion, and mutation, can disrupt epigenetics, transcriptional regulation, and tumor microenvironment interactions, leading to cancer development. Targeting these kinase mutations with small molecule drugs or antibodies has shown clinical benefits. For example, erdafitinib is approved for treating locally advanced or metastatic urothelial cancer patients with FGFR2/FGFR3 mutations, and pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement. Effective screening of FGFR variant patients is crucial for the clinical application of FGFR inhibitors. Various detection methods, such as polymerase chain reaction, next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry, are available, and their selection should be based on diagnostic and treatment decision-making needs. Our developed expert consensus aims to standardize the diagnosis and treatment process for FGFR gene mutations and facilitate the practical application of FGFR inhibitors in clinical practice.
Source: Global Medical Genetics
Authors: Chunwei Xu, Bin Lian, Juanjuan Ou, Qian Wang, Wenxian Wang, Ke Wang, Dong Wang, Zhengbo Song, Aijun Liu, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Lili Mao, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Long Huang, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Fei Pang, Jintao Huang, Kai Wang, Fan Wu, Bingwei Xu, Liping Wang, Youcai Zhu, Li Lin, Yanru Xie, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Jia Wei, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yue Feng, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Zhaofeng Wang, Yue Hao, Zhen Wang, Bin Wan, Donglai Lv, Zhanqiang Zhai, Shengjie Yang, Jing Kang, Jiatao Zhang, Chao Zhang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Zhefeng Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Jing Chen, Yiping Zhang, Xixu Zhu, Yi Shen, Shenglin Ma, Biyun Wang, Lu Si, Yuanzhi Lu, Ziming Li, Wenfeng Fang, Yong Song
Institutions: Chinese Academy of Sciences, Nanjing General Hospital of Nanjing Military Command, Nanjing University, Peking University Cancer Hospital, Army Medical University, Southwest Hospital, Nanjing University of Chinese Medicine, Zhejiang Cancer Hospital, National Health and Family Planning Commission, Nanjing Medical University, Chinese PLA General Hospital, Second Affiliated Hospital of Nanchang University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Molecular Oncology, Central South University, Hunan Cancer Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Jilin Province Tumor Hospital, Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine, Zhejiang University, Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Second Affiliated Hospital of Zhejiang University, Nanjing Drum Tower Hospital, Yangzhou University, Fujian Medical University, Fujian Provincial Cancer Hospital, Renmin Hospital of Wuhan University, Peking University, Beijing Jishuitan Hospital, Ningbo No. 2 Hospital, University of Chinese Academy of Sciences, Wenzhou Medical University, Chinese People's Liberation Army, Capital Medical University, Beijing Tian Tan Hospital, Peking University International Hospital, First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Shanxi Academy of Medical Sciences, Tongji University, Shanghai East Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Tongji Hospital, Huazhong University of Science and Technology, Wuhan Union Hospital, Xiamen University, First Affiliated Hospital of Xiamen University, China Medical University, University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Fudan University Shanghai Cancer Center, National Clinical Research Center for Digestive Diseases, Xijing Hospital, First Affiliated Hospital of Jinan University, State Key Laboratory of Cancer Biology, Air Force Medical University, Jiangsu Province Hospital, Fudan University, Huadong Hospital, Jilin University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Jiaxing University, Lishui Central Hospital, First Hospital of China Medical University, Shandong University, Qilu Hospital of Shandong University, Second Military Medical University, Shanghai Changzheng Hospital, First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital, Sun Yat-sen University, Shanghai Jiao Tong University, Shanghai Chest Hospital, Second Affiliated Hospital of Jilin University, Zhengzhou University, Henan Cancer Hospital, Nanjing Jiangning Hospital, The People's Hospital of Chuxiong Yi Autonomous Prefecture, Shanghai Medical College of Fudan University, Zhongshan Hospital, First Affiliated Hospital Zhejiang University, Guilin Medical University, Jinan University, Xinqiao Hospital, Sir Run Run Shaw Hospital, Hangzhou Cancer Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,500
OpenAlex ID: W4402845910